GUIDELINES - The Endocrine Society

of potassium levels and angiotensin responsiveness. ClinExp Pharmacol Physiol 21:319–22114. Young WF, Jr. 2003 Minireview: primary aldosteronism--changing concepts in diagnosis and treatment.Endocrinology 144:2208–13115. Lo CY, Tam PC, Kung AW, Lam KS, Wong J 1996Primary aldosteronism. Results of surgical treatment. AnnSurg 224:125–30116. Proye CA, Mulliez EA, Carnaille BM, Lecomte-HouckeM, Decoulx M, Wemeau JL, Lefebvre J, Racadot A, ErnstO, Huglo D, Carre A 1998 Essential hypertension: firstreason for persistent hypertension after unilateraladrenalectomy for primary aldosteronism? Surgery124:1128–33117. Jacobsen NE, Campbell JB, Hobart MG 2003Laparoscopic versus open adrenalectomy for surgicaladrenal disease. Can J Urol 10:1995–9118. Rutherford JC, Stowasser M, Tunny TJ, Klemm SA,Gordon RD 1996 Laparoscopic adrenalectomy. World JSurg 20:758–60; discussion 761119. Ishidoya S, Ito A, Sakai K, Satoh M, Chiba Y, Sato F,Arai Y 2005 Laparoscopic partial versus totaladrenalectomy for aldosterone producing adenoma. J Urol174:40–3120. Ghose RP, Hall PM, Bravo EL 1999 Medical managementof aldosterone-producing adenomas. Ann Intern Med131:105–8121. Sywak M, Pasieka JL 2002 Long-term follow-up and costbenefit of adrenalectomy in patients with primaryhyperaldosteronism. Br J Surg 89:1587–93122. Mattsson C, Young WF, Jr. 2006 Primary aldosteronism:diagnostic and treatment strategies. Nat Clin Pract Nephrol2:198–208123. Rutherford JC, Taylor WL, Stowasser M, Gordon RD1998 Success of surgery for primary aldosteronism judged byresidual autonomous aldosterone production. World J Surg22:1243–5124. Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E,Lever AF, Robertson JI 1972 Comparison of surgery andprolonged spironolactone therapy in patients withhypertension, aldosterone excess, and low plasma renin. BrMed J 2:729–34125. Crane MG, Harris JJ 1970 Effect of spironolactone inhypertensive patients. Am J Med Sci 260:311–30126. Ganguly A, Luetscher JA 1976 Spironolactone therapy inprimary aldosteronism: diagnostic and therapeuticimplications. In: Sambhi MP (ed) Systemic effects ofantihypertensive agents. Stratton, New York; pp 383–392127. Helber A, Wambach G, Hummerich W, Bonner G,Meurer KA, Kaufmann W 1980 Evidence for a subgroup ofessential hypertensives with non-suppressible excretion ofaldosterone during sodium loading. Klin Wochenschr58:439–47128. Kater CE, Biglieri EG, Schambelan M, Arteaga E 1983Studies of impaired aldosterone response to spironolactoneinducedrenin and potassium elevations in adenomatous butnot hyperplastic primary aldosteronism. Hypertension5:V115–21129. Kremer D, Beevers DG, Brown JJ, Davies DL, FerrissJB, Fraser R, Lever AF, Robertson JI 1973Spironolactone and amiloride in the treatment of low reninhyperaldosteronism and related syndromes. Clin Sci MolMed Suppl 45 Suppl 1:213s–8130. Wambach G, Helber A, Bonner G, Hummerich W,Meurer KA, Kaufmann W 1980 [Spironolactone inessential hypertension associated with abnormalaldosterone regulation and in Conn’s syndrome (author'stransl)]. Dtsch Med Wochenschr 105:647–51131. Lim PO, Jung RT, MacDonald TM 1999 Raisedaldosterone to renin ratio predicts antihypertensive efficacyof spironolactone: a prospective cohort follow-up study. BrJ Clin Pharmacol 48:756–60132. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A,DeVries C, Plouin PF, Corvol P, Menard J 1987 Efficacyand tolerance of spironolactone in essential hypertension.Am J Cardiol 60:820–5133. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE,Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, GrobJ, Schmidlin J, et al. 1987 Three new epoxy-spirolactonederivatives: characterization in vivo and in vitro. JPharmacol Exp Ther 240:650–6134. Burgess ED, Lacourciere Y, Ruilope-Urioste LM, OparilS, Kleiman JH, Krause S, Roniker B, Maurath C 2003Long-term safety and efficacy of the selective aldosteroneblocker eplerenone in patients with essential hypertension.Clin Ther 25:2388–404135. Weinberger MH, Roniker B, Krause SL, Weiss RJ 2002Eplerenone, a selective aldosterone blocker, in mild-tomoderatehypertension. Am J Hypertens 15:709–16136. Pitt B, Remme W, Zannad F, Neaton J, Martinez F,Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M2003 Eplerenone, a selective aldosterone blocker, inpatients with left ventricular dysfunction after myocardialinfarction. N Engl J Med 348:1309–21137. Lim PO, Young WF, MacDonald TM 2001 A review of themedical treatment of primary aldosteronism. J Hypertens19:353–61138. Farquharson CA, Struthers AD 2000 Spironolactoneincreases nitric oxide bioactivity, improves endothelialvasodilator dysfunction, and suppresses vascularangiotensin I/angiotensin II conversion in patients withchronic heart failure. Circulation 101:594–7139. Farquharson CA, Struthers AD 2002 Increasing plasmapotassium with amiloride shortens the QT interval andreduces ventricular extrasystoles but does not changeendothelial function or heart rate variability in chronicheart failure. Heart 88:475–80CASE DETECTION, DIAGNOSIS, AND TREATMENT OF PA TIENTS WITH PRIMARY ALDOSTERONISM25